Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3315141
Max Phase: Preclinical
Molecular Formula: C55H68N10O11S2
Molecular Weight: 1109.34
Molecule Type: Protein
Associated Items:
ID: ALA3315141
Max Phase: Preclinical
Molecular Formula: C55H68N10O11S2
Molecular Weight: 1109.34
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)[C@@H]1CSSC(C)(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCN)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C55H68N10O11S2/c1-30(2)45(54(75)76)64-52(73)43-29-77-78-55(3,4)46(65-47(68)37(57)27-44(66)67)53(74)62-40(24-31-13-6-5-7-14-31)49(70)61-42(26-35-28-58-38-18-11-10-17-36(35)38)51(72)59-39(19-12-22-56)48(69)60-41(50(71)63-43)25-32-20-21-33-15-8-9-16-34(33)23-32/h5-11,13-18,20-21,23,28,30,37,39-43,45-46,58H,12,19,22,24-27,29,56-57H2,1-4H3,(H,59,72)(H,60,69)(H,61,70)(H,62,74)(H,63,71)(H,64,73)(H,65,68)(H,66,67)(H,75,76)/t37-,39-,40-,41-,42+,43-,45-,46+/m0/s1
Standard InChI Key: YMTXTDLKMZAORN-FOIRLTBOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1109.34 | Molecular Weight (Monoisotopic): 1108.4510 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Carotenuto A, Auriemma L, Merlino F, Yousif AM, Marasco D, Limatola A, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P.. (2014) Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor., 57 (14): [PMID:24992374] [10.1021/jm500218x] |
Source(1):